Synergistic interaction of hyperuricemia and hypertension on reduced eGFR: insights from a general Chinese population

References

• Webster A, Nagler E, Morton R, et al. Chronic Kidney Disease. Lancet. 2017;389(10075):1238–1252.
   PubMed Web of Science ®Google Scholar
• Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet. 2012;379(9818):815–822.
   PubMed Web of Science ®Google Scholar
• Horowitz B, Miskulin D, Zager P. Epidemiology of hypertension in CKD. Adv Chronic Kidney Dis. 2015 Mar;22(2):88–95.
   PubMed Web of Science ®Google Scholar
• Levey A, Astor B, Stevens L, et al. Chronic kidney disease, diabetes, and hypertension: what’s in a name?. Kidney Int. 2010;78(1):19–22.
   PubMed Web of Science ®Google Scholar
• Muntner P, Anderson A, Charleston J, et al. Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis. 2010 Mar;55(3):441–451.
   PubMed Web of Science ®Google Scholar
• Rao MV, Qiu Y, Wang C, et al. Hypertension and CKD: kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES), 1999-2004. Am J Kidney Dis. 2008 Apr;51(4 Suppl 2):S30–7.
   PubMed Web of Science ®Google Scholar
• Perry HM Jr., Miller JP, Fornoff JR, et al. Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension. 1995 Apr;25(4 Pt 1):587–594. (Dallas, Tex: 1979).
   PubMed Web of Science ®Google Scholar
• Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996 Jan 4;334(1):13–18.
   PubMed Web of Science ®Google Scholar
• Pohl MA, Blumenthal S, Cordonnier DJ, et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol. 2005 Oct;16(10):3027–3037.
   PubMed Web of Science ®Google Scholar
• Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med. 2003 Aug 19;139(4):244–252.
   PubMed Web of Science ®Google Scholar
• Bidani AK, Polichnowski AJ, Loutzenhiser R, et al. Renal microvascular dysfunction, hypertension and CKD progression. Curr Opin Nephrol Hypertens. 2013 Jan;22(1):1–9.
   PubMed Web of Science ®Google Scholar
• Tomita M, Mizuno S, Yamanaka H, et al. Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers. J Epidemiol. 2000 Nov;10(6):403–409.
   PubMedGoogle Scholar
• Iseki K, Ikemiya Y, Inoue T, et al. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis. 2004 Oct;44(4):642–650.
   PubMed Web of Science ®Google Scholar
• Chonchol M, Whittle J, Desbien A, et al. Chronic kidney disease is associated with angiographic coronary artery disease. Am J Nephrol. 2008;28(2):354–360.
   PubMed Web of Science ®Google Scholar
• Chao MC, Hu SL, Hsu HS, et al. Serum homocysteine level is positively associated with chronic kidney disease in a Taiwan Chinese population. J Nephrol. 2014 Jun;27(3):299–305.
   PubMed Web of Science ®Google Scholar
• Goicoechea M, Garcia de Vinuesa S, Verdalles U, et al. Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial. American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation. 2015 Apr;65(4):543–549.
   PubMed Web of Science ®Google Scholar
• Chou HW, Chiu HT, Tsai CW, et al. Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study. Nephrol Dialysis Trans. 2018 Sep 1;33(9):1620–1627.
   PubMed Web of Science ®Google Scholar
• Liu X, Zhai T, Ma R, et al. Effects of uric acid-lowering therapy on the progression of chronic kidney disease: a systematic review and meta-analysis. Ren Fail. 2018 Nov;40(1):289–297.
   PubMed Web of Science ®Google Scholar
• Su X, Xu B, Yan B, et al. Effects of uric acid-lowering therapy in patients with chronic kidney disease: A meta-analysis. PLoS One. 2017;12(11):e0187550.
   PubMed Web of Science ®Google Scholar
• Bose B, Badve SV, Hiremath SS, et al. Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. Nephrol Dialysis Trans. 2014 Feb;29(2):406–413.
   PubMed Web of Science ®Google Scholar
• Talaat KM, el-Sheikh AR. The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease. Am J Nephrol. 2007;27(5):435–440.
   PubMed Web of Science ®Google Scholar
• Kohagura K, Kochi M, Miyagi T, et al. An association between uric acid levels and renal arteriolopathy in chronic kidney disease: a biopsy-based study. Hypertens Res. 2013 Jan;36(1):43–49.
   PubMed Web of Science ®Google Scholar
• Sanchez-Lozada LG, Tapia E, Santamaria J, et al. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int. 2005 Jan;67(1):237–247.
   PubMed Web of Science ®Google Scholar
• Shi WR, Wang HY, Chen S, et al. Estimate of prevalent diabetes from cardiometabolic index in general Chinese population: a community-based study. Lipids Health Dis. 2018 Oct 12;17(1):236.
   PubMedGoogle Scholar
• Shi WR, Wang HY, Chen S, et al. The impact of monocyte to high-density lipoprotein ratio on reduced renal function: insights from a large population. Biomark Med. 2019;13(9):773-783.
   Web of Science ®Google Scholar
• Wang HY, Shi WR, Yi X, et al. Assessing the performance of monocyte to high-density lipoprotein ratio for predicting ischemic stroke: insights from a population-based Chinese cohort. Lipids Health Dis. 2019 May 30;18(1):127.
   PubMedGoogle Scholar
• Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009 May 5;150(9):604–612.
   PubMed Web of Science ®Google Scholar
• Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet. 2012 Mar 3;379(9818):815–822.
   PubMed Web of Science ®Google Scholar
• Stevens P, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158(11):825–830.
   PubMed Web of Science ®Google Scholar
• Chobanian A, Bakris G, Black H, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA. 2003;289(19):2560–2572.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Classification and Diagnosis of Diabetes. Diabetes Care. 2018;41(Suppl1):S13–S27.
   PubMedGoogle Scholar
• Liu R, Han C, Wu D, et al. Prevalence of hyperuricemia and gout in Mainland China from 2000 to 2014: A systematic review and meta-analysis. Biomed Res Int. 2015;2015:762820.
   PubMed Web of Science ®Google Scholar
• Kendler KS, Gardner CO. Interpretation of interactions: guide for the perplexed. Br J Psychiatry. 2010 Sep;197(3):170–171.
   PubMed Web of Science ®Google Scholar
• Knol MJ, van der Tweel I, Grobbee DE, et al. Estimating interaction on an additive scale between continuous determinants in a logistic regression model. Int J Epidemiol. 2007 Oct;36(5):1111–1118.
   PubMed Web of Science ®Google Scholar
• Andersson T, Alfredsson L, Kallberg H, et al. Calculating measures of biological interaction. Eur J Epidemiol. 2005;20(7):575–579.
   PubMed Web of Science ®Google Scholar
• Assmann SF, Hosmer DW, Lemeshow S, et al. Confidence intervals for measures of interaction. Epidemiology. 1996 May;7(3):286–290. (Cambridge, Mass).
   PubMed Web of Science ®Google Scholar
• Li R, Chambless L. Test for additive interaction in proportional hazards models. Ann Epidemiol. 2007 Mar;17(3):227–236.
   PubMed Web of Science ®Google Scholar
• Rothman KJ, Greenland S, Walker AM. Concepts of interaction. Am J Epidemiol. 1980 Oct;112(4):467–470.
   PubMed Web of Science ®Google Scholar
• Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007 Oct 16;4(10):e297.
   PubMed Web of Science ®Google Scholar
• Cheung AK, Rahman M, Reboussin DM, et al. Effects of Intensive BP Control in CKD. J Am Soc Nephrol. 2017 Sep;28(9):2812–2823.
   PubMed Web of Science ®Google Scholar
• Cain L, Shankar A, Ducatman AM, et al. The relationship between serum uric acid and chronic kidney disease among Appalachian adults. Nephrol Dialysis Trans. 2010 Nov;25(11):3593–3599.
   PubMed Web of Science ®Google Scholar
• Chou YC, Kuan JC, Yang T, et al. Elevated uric acid level as a significant predictor of chronic kidney disease: a cohort study with repeated measurements. J Nephrol. 2015 Aug;28(4):457–462.
   PubMed Web of Science ®Google Scholar
• Jalal DI, Rivard CJ, Johnson RJ, et al. Serum uric acid levels predict the development of albuminuria over 6 years in patients with type 1 diabetes: findings from the Coronary Artery Calcification in Type 1 Diabetes study. Nephrol Dialysis Trans. 2010 Jun;25(6):1865–1869.
   PubMed Web of Science ®Google Scholar
• Cristobal-Garcia M, Garcia-Arroyo FE, Tapia E, et al. Renal oxidative stress induced by long-term hyperuricemia alters mitochondrial function and maintains systemic hypertension. Oxid Med Cell Longev. 2015;2015:535686.
   PubMed Web of Science ®Google Scholar
• Sanchez-Lozada LG, Lanaspa MA, Cristobal-Garcia M, et al. Uric acid-induced endothelial dysfunction is associated with mitochondrial alterations and decreased intracellular ATP concentrations. Nephron Exp Nephrol. 2012;121(3–4):e71–8.
   PubMedGoogle Scholar